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ABSTRACT
Objectives Mitral valve (MV) tenting parameters are 
indicators of left ventricular remodelling severity and may 
predict outcome in functional mitral regurgitation (FMR). 
We hypothesised that indexing of MV tenting area to body 
surface area (BSA), to mitral annulus diameter or gender- 
adjusted analysis of tenting parameters may improve their 
prognostic value.
Methods We identified retrospectively 240 patients with 
consecutive FMR (mean age 68±10 years; men=135) 
from our institutional database who underwent isolated 
MV annuloplasty during a period of 7 years (2010–2016). 
Using preoperative two- dimensional transthoracic 
echocardiographic images, MV tenting parameters 
including tenting area, tenting height and annulus 
diameter were systematically assessed. Follow- up 
protocol consisted of chart review and structured clinical 
questionnaire. Primary study endpoint was the composite 
of death and adverse cardiac events (ie, MV reoperation, 
cardiac resynchronisation therapy implantation, ventricular 
assist device implantation or heart transplantation).
Results BSA- indexed MV tenting area was identified 
as independent predictor of primary study endpoint 
(HR 1.9; 95% CI 1.1 to 3.5; p=0.02). After cut- off point 
analysis, BSA- indexed MV tenting area >1.35 cm2/m2 was 
significantly associated with primary study outcome (HR 
2.3; 95% CI 1.3 to 4.0; p=0.003). Annulus- indexed MV 
tenting area showed only a tendency towards primary 
study endpoint prediction (HR 2.8; 95% CI 0.6 to 12.6; 
p=0.17). Between female and male patients, BSA- indexed 
MV tenting area was similar (1.42±0.4 cm2/m2 vs 
1.45±0.4cm2/cm2; p=0.6) and gender was not associated 
with primary study outcome (HR 0.8; 95% CI 0.5 to 1.4; 
p=0.5).
Conclusion In our FMR cohort, BSA- indexed MV tenting 
area showed the strongest association with negative 
outcomes following isolated MV annuloplasty. Patients 
with BSA- indexed MV tenting area >1.35cm2/m2 could 
potentially benefit from additional surgical maneuvers 
addressing left ventricular remodelling.
INTRODUCTION
Progressive left ventricular remodelling is 
frequently followed by a functional regurgi-
tation of the structurally normal mitral valve 
(FMR).1 Due to papillary muscle displace-
ment, increased tethering forces on mitral 
chordae and annular dilatation, mitral valve 
(MV) leaflets lose their coaptation and take 
shape of a tent during systole.2 Typically, the 
triangular area between mitral annulus and 
tented leaflets is described as MV tenting area.3 
MV tenting area can be quantitatively assessed 
by echocardiography and reflects both the 
global and regional left ventricular remodel-
ling.3 4 Severity of MV tenting has been shown 
to correlate with prognosis of patients with 
FMR.5–9 Recurrent mitral regurgitation (MR), 
heart failure and death occurred more often 
in patients with FMR with a preoperative MV 
tenting area >2.5 cm2.5–9 Though, it is difficult 
Key questions
What is already known about this subject?
 ► Severity of mitral valve (MV) tenting (ie, MV tenting 
area >2.4 cm2) was previously shown to correlate 
with negative outcomes in patients with functional 
mitral regurgitation (FMR).
What does this study add?
 ► In our study, we focused on confounding factors of 
MV tenting area including body shape (BSA), MV 
geometry (annulus diameter) and gender. We were 
able to demonstrate that BSA- adjusted MV tenting 
area >1.35 cm2/m2 is a reliable echocardiographic 
marker predicting reduced survival and lower free-
dom of adverse cardiac events following isolated MV 
annuloplasty.
How might this impact on clinical practice?
 ► Patients with FMR should preoperatively under-
go detailed echocardiographic examination with 
assessment of tenting parameters including BSA- 
indexed tenting area. Surgical treatment strategy 
of FMR should be adapted according to these mea-
surements. In patients with FMR with a BSA- indexed 
tenting area >1.35 cm2/m2, we strongly recommend 
performing MV annuloplasty with simultaneous sub-
annular repair.  on F
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to interpret MV tenting area without looking at poten-
tial confounding factors: (1) MV tenting area does not 
consider the variance in body shape of patients with FMR. 
Larger individuals have normally larger heart size and, 
therefore, larger absolute tenting area.10 (2) MV tenting 
area does not adjust for MV annulus diameter, which may 
vary significantly among individuals with different forms 
of FMR (‘atrial vs ventricular FMR type; figure 1).11 (3) 
Absolute MV tenting area does not reflect potential gender 
differences. Female patients are known to have smaller left 
ventricle (LV) volumes in FMR and still experience higher 
mortality in comparison to men.12 13 Therefore, adjustment 
of tenting parameters to the individual anatomy seems 
to be reasonable and could improve the predictive value 
of tenting parameters to enable an individualised treat-
ment strategy14 15 However, the evidence of individualised 
imaging markers (ie, indexed to body surface area (BSA) or 
sex) in FMR is very sparse. Herewith, we assessed preopera-
tive MV tenting area in patients with FMR and adjusted MV 
tenting area to BSA, mitral annulus diameter and gender. 
We hypothesised that severity of indexed MV tenting is 
associated with the outcome after MV surgery in patients 
with FMR. Second, we aimed to identify those patients with 
FMR, who are not sufficiently treated by an isolated mitral 
annuloplasty and could potentially benefit from modified 
surgical strategy (ie, subannular MV repair).
METHODS
Study design
In our study, we retrospectively reviewed 1661 patients from 
our institutional MV database who underwent MV surgery 
for MV regurgitation from January 2010 to December 2016. 
Only patients with FMR disease (n=521) were included in 
our analysis (figure 2). Further patients were excluded 
(n=259) due to incorrect storage of echocardiographic 
images or insufficient image quality to measure tenting 
parameters. Finally, a total of 240 patients with FMR who 
underwent an isolated MV annuloplasty (ie, without addi-
tional leaflet manoeuvres or subannular repair) served as 
our study population. We included most recent long- term 
follow- up data with a mean follow- up period for the whole 
study cohort of 43±25 months. Preliminary results with a 
limited follow- up had been previously published by our 
group.5
Individual patient consent was waived. Patients or 
public were not involved in our study design.
Echocardiographic assessment of tenting parameter
Preoperative two- dimensional (2D) transthoracic echo-
cardiography was routinely performed in our echocardi-
ographic core laboratory within 1 week prior to surgery. 
Echocardiographic images were systematically analysed 
by two independent investigators (MvS and TS- G). Using 
a standardised protocol, MV tenting was assessed in the 
parasternal- long axis view during late systole according 
to the recommendations for the assessment of valvular 
regurgitation of the European Association of Echocar-
diography.3 The extent of MV tenting was assessed by 
tenting area (cm2) and tenting height (mm) (figure 3). 
Annulus diameter was also measured in the parasternal- 
long axis view during late systole representing the anter-
oposterior diameter.
Surgical mitral annuloplasty
Surgical approach to FMR was either median sternotomy 
or right anterolateral mini- thoracotomy, depending on 
concomitant cardiac procedures and patients’ comor-
bidities. FMR was treated using a standard rigid or semi-
rigid complete annuloplasty ring, which was downsized 
by one size, according to the length of the anterior mitral 
leaflet. There were no major variations in the surgical 
Figure 1 Illustration of individual variations of tenting area (purple triangle), annulus diameter and left ventricular remodelling. 
A mitral valve tenting area of 3.0 cm2 can be found in patients with severe left ventricular remodelling (annulus diameter 40 mm; 
tenting height 15 mm) (A) and in patients with severe annular dilatation (annulus diameter 60 mm; tenting height 10 mm) (B). 
Therefore, ‘absolute’ tenting area does not reflect on annular dilatation. FMR, functional mitral regurgitation.
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management and perioperative treatment protocol 
during the study period. Baseline heart failure medica-
tion was maintained during the perioperative period and 
included aspirin, lipid- lowering agents, beta- blockers, 
ACE inhibitors and diuretics.
Clinical outcome and follow-up
Clinical outcomes of interest were defined as all- cause 
mortality and adverse cardiac events, which consisted 
of MV reoperation, cardiac resynchronisation therapy 
(CRT) implantation, ventricular assist device (VAD) 
implantation or heart transplantation. Primary study 
endpoint was a composite of death and adverse cardiac 
events.
All patients underwent regularly scheduled follow- up 
visits in outpatient heart failure units and their medical 
records were analysed. Furthermore, all patients were 
contacted by a telephone interview using a standardised 
clinical outcome questionnaire.
Statistical analysis
Normally distributed continuous variables are presented 
as mean±SD and categorical variables are expressed as 
percentages throughout the manuscript. Comparison of 
normally distributed continuous variables was performed 
by unpaired t- test. Fisher’s exact test was used for univar-
iable comparisons of categorical variables. A Pearson 
correlation coefficient was used for correlation analyses.
Overall survival and freedom of adverse cardiac events 
in study groups were compared using univariable log- 
rank test (Kaplan- Meier method). Predictors of primary 
endpoint variable were subsequently assessed by multi-
variable Cox regression analysis. All p values<0.05 were 
considered statistically significant. All statistical analyses 
Single-Centre Mitral Valve Surgery Database (n = 1661) 
Retrospective review from 01/2010 till 12/2016)
• Degenerative MR (n = 801)
• Mitral valve stenosis (n = 154)
• Infective endocarditis (n = 134)
• Papillary muscle rupture (n = 8)
• Congenital heart disease (n = 7)
• Cardiac trauma (n = 1) 
• Previous mitral valve surgery (n = 20)
• Previous Mitraclip (n = 15)
• Mitral valve replacement (n = 22)
• Missing imaging data (n = 198 )




Group 1 > 1.35 cm2/m2 (n = 129)  
Group 2 ≤ 1.35 cm2/m2 (n = 111)
FMR patients with isolated mitral annuloplasty and assessment of preoperative tenting parameters (n = 240)
Subgroup 
Tenting area / Annulus Diameter
Group 1 > 0.76cm2/cm (n = 92)
Group 2 ≤ 0.76cm2/cm (n = 148)
Subgroup 
Gender
Males (n = 135)
Females (n = 105)
Figure 2 Flow chart of study design and patient selection. BSA, body surface area; FMR, functional mitral regurgitation; MR, 
mitral regurgitation.
Figure 3 Measurement of tenting parameter by transthoracic two- dimensional echocardiography in the parasternal- long axis 
view during late systole: (A) tenting area (yellow area), (B) tenting height (yellow line) and annulus diameter (blue line). Ao, Aorta; 
LA, left atrium; LV, left ventricle.
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were performed using the SPSS V.26.0 statistical package 
(IBM Corp.).
Post-hoc analyses of BSA-indexed, annulus-indexed and 
gender-indexed MV tenting area
Tenting area was indexed to BSA and annular diameter by 
simple division of variables without additional weighting 
factors. BSA (m2) was calculated using the formula of 
Mosteller.16 To investigate associations between tenting 
area versus BSA and tenting area versus annular diameter 
we performed bivariate (Pearson) correlations. To demon-
strate associations between gender and tenting area, 
we used a χ2 test. For prognostic assessment of indexed 
tenting area and gender on clinical outcome, multivariable 
analyses were performed for each parameter using a Cox 
proportional hazards regression model of six covariates, 
which showed p<0.1 in the previous univariable analysis or 
were clinically relevant. In addition, we calculated receiver 
operating characteristic (ROC) curves to determine 
optimal cut- off points of BSA and annulus- indexed tenting 
area to predict primary study endpoint. The optimal cut- off 
value was defined by Youden index.
RESULTS
Demographics and baseline characteristics
A total of 240 consecutive patients (mean age 68.0±9.8 
years, 135 men) were analysed. Ischaemic cardiomyo-
pathy was found in 135 (56.3%) patients, the remaining 
105 patients had a non- ischaemic cardiomyopathy. Risk 
score calculations revealed mean logistic EuroSCORE II 
of 7.1%±8.9% and Society of Thoracic Surgery Score of 
3.4%±3.5%, respectively. Isolated MV annuloplasty was 
performed in 58 (23%) patients with FMR, while 184 
(77%) patients underwent concomitant procedures (ie, 






















Male (%) 135 (56.3) 72 (55.8) 63 (56.8) 0.88 53 (55.4) 82 (57.6) 0.74 – – –
Age (years) 68.0±9.8 67.5±9.8 68.4±9.7 0.59 67.1±10.1 68.4±4.3 0.33 68.1±9.8 67.2±8.2 0.17
BSA (m2) 1.9±0.2 1.9±0.2 2.0±0.2 0.04 2.0±0.2 1.9±0.2 0.37 1.8±0.2 2.0±0.1 <0.001
Diabetes (%) 44 (18.3) 24 (18.2) 20 (18.6) 0.93 18 (17.7) 26 (19.6) 0.72 16 (15.2) 28 (20.9) 0.24
Creatinine (mg/dL) 1.3±0.8 1.4±1.0 1.2±0.6 0.11 1.4±1.0 1.3±0.7 0.31 1.3±0.5 1.3±0.7 0.96
CAD (%) 127 (52.9) 66 (51.6) 61 (55.0) 0.56 51 (55.4) 76 (51.4) 0.54 37 (35.2) 90 (66.7) <0.001
Acute HF (%) 107 (44.6) 66 (51.6) 41 (36.9) 0.02 45 (49.5) 62 (41.9) 0.25 46 (43.8) 61 (45.5) 0.79
LVEF (%) 46±12 44±12 49±12 0.01 43±13 48±12 0.04 49±11 44±13 0.04
Ischaemic CM 135 (56.3) 73 (56.6) 62 (55.9) 0.91 78 (52.7) 57 (62) 0.16 42 (40) 93 (68.9) <0.001
Non- ischaemic CM 105 (43.7) 56 (43.4) 49 (44.1) 0.91 70 (47.3) 35 (38) 0.16 63 (60) 42 (31.1) <0.001
STS Score (%) 3.4±3.5 3.5±3.9 3.2±3.0 0.58 3.2±2.4 3.4±4.0 0.68 3.6±4.5 3.2±3.5 0.33
EuroSCORE II (%) 7.1±8.9 7.0±8.5 7.3±9.4 0.83 7.5±8.9 6.9±8.9 0.65 7.4±9.9 7.0±8.2 0.71
Ring size (mm) 29.9±1.6 29.9±1.8 30.0±1.7 0.69 30.0±1.8 29.9±1.7 0.64 29.3±1.6 30.5±1.7 <0.001
Concomit. proc. (%) 184 (76.7) 97 (75.2) 87 (78.4) 0.56 67 (79.1) 117 (72.8) 0.76 71 (67.6) 113 (83.7) 0.003
CABG (%) 94 (39.2) 41 (31.8) 53 (47.7) 0.01 33 (35.9) 61 (41.2) 0.41 23 (21.9) 71 (52.6) <0.001
Continuous values presented means±SD; categorial values presented as no. (%).
Acute HF, decompensated heart failure within two weeks before surgery; BSA, body surface area (m2); CABG, coronary artery bypass grafting; CAD, 
Coronary artery disease; CM, cardiomyopathy; LVEF, left ventricle ejection fraction; STS Score, Society of Thoracic Surgery risk score for mortality.
Table 2 Preoperative tenting parameters (presented as mean values and separated by gender)
Tenting parameter All (n=240) Males (n=135) Females (n=105) P value
Annulus diameter (mm) 37.3±5.4 38.6±5.5 36.2±5.1 0.001
BSA- adjusted annulus diameter (cm/m2) 19.4±3.0 18.8±2.8 20.1±3.1 0.003
Tenting area (cm2) 2.8±0.8 2.9±0.8 2.6±0.7 0.017
BSA- adjusted tenting area (cm2/m2) 1.43±0.4 1.42±0.4 1.45±0.4 0.58
Tenting height (mm) 11.4±2.8 11.9±2.9 10.9±2.6 0.009
BSA- adjusted tenting height (mm/m2) 6.0±1.5 5.9±1.6 6.1±1.5 0.315
Continuous values presented means±SD
BSA, body surface area.
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coronary artery bypass grafting (CABG), tricuspid valve 
surgery, aortic valve surgery; table 1).
Preoperative assessment of echocardiographic MV 
tenting parameters revealed mean tenting area of 
2.8±0.8 cm2 and mean anteroposterior annulus diameter 
of 3.7±0.5 cm. Mean BSA was 1.9±0.2 m2 (table 2).
In the whole study cohort, 51/240 (21.2%) patients 
died and 14/240 (5.8%) patients experienced an adverse 
cardiac event including MV reoperation (n=6), CRT 
implantation (n=4), VAD implantation (n=3) and heart 
transplantation (n=1) during follow- up. Calculated by 
Kaplan- Meier analysis, overall cardiac adverse event free 
survival was 70.8%±3.4% at 5 years in the whole study 
cohort.
BSA-indexed MV tenting area
We found a significant correlation between tenting area 
and BSA (Pearson r=0.216; p=0.01). Indexation of tenting 
area to BSA revealed a normally distributed variable with 
a mean value of 1.43±0.4 cm2/m2 (minimum 0.57 cm2/
m2–maximum 2.67 cm2/m2). In the multivariable anal-
ysis, BSA- indexed MV tenting area was identified as inde-
pendent predictor of composite primary endpoint (HR 1.9; 
95% CI 1.1 to 3.5; p=0.02; table 3). Optimal cut- off point 
of BSA- indexed MV tenting area, as identified by ROC 
analysis, was 1.35 cm2/m2. Subsequently, we subdivided 
our study cohort into 111 patients with a BSA- indexed MV 
tenting area ≤1.35 cm2/m2 and 129 patients with a BSA- 
indexed MV tenting area >1.35 cm2/m2. As expected, base-
line characteristics of both subgroups revealed significant 
differences (table 1). Those patients with BSA- indexed MV 
tenting area >1.35 cm2/m2 presented with a worse baseline 
left ventricle ejection fraction (LVEF), had more often 
decompensated heart failure (ie, cardiac decompensation 
within 2 weeks before surgery) and underwent less concom-
itant CABG surgery. Overall, 44/129 (34.1%) patients with 
BSA- indexed MV tenting area >1.35 cm2/m2 died or had 
an adverse cardiac event during the follow- up period versus 
21/111 (18.9%) patients with BSA- indexed MV tenting area 
≤1.35 cm2/m2. In Kaplan- Meier analysis, BSA- indexed MV 
tenting area >1.35 cm2/m2 was significantly associated with 
the primary study outcome (p(log- rank)=0.002) (figure 4A). In 
addition, multivariable analysis revealed that patients with 
a BSA- indexed MV tenting area >1.35 cm2/m2 had a 2.3 
times greater risk for experiencing primary study endpoint 
(HR 2.3; 95% CI 1.3 to 4.0; p=0.003; table 3).
Tenting area indexed by annulus diameter
MV tenting area showed a strong correlation with the 
anteroposterior annulus diameter (Pearson r=0.663, 
p<0.0001). Indexation of tenting area to annulus diam-
eter revealed a normally distributed variable with a 
mean value of 0.74 cm2/cm (minimum 0.34 cm2/m2–
maximum 1.31 cm2/cm). Annulus- indexed MV tenting 
area showed only a tendency towards an association with 
primary study endpoint in the multivariable analysis (HR 
2.8; 95% CI 0.6 to 12.6; p=0.17; table 3). Optimal cut- off 
point of annulus- indexed MV tenting area, as identified 
by ROC analysis, was 0.76 cm2/cm. We subdivided our 
study cohort into 148 patients with annulus- indexed MV 
tenting area <0.76 cm2/cm and 92 patients with annulus- 
indexed MV tenting area >0.76 cm2/cm. Both subgroups 
had comparable baseline characteristics (table 1).
Table 3 Predictors of the composite of survival and 
freedom of cardiac adverse events
  ß P value HR CI
Impact of BSA- adjusted tenting area
  Age 0.00 0.98 1.00 0.97 to 1.03
  Log. EuroScore II 0.02 0.04 1.02 0.99 to 1.05
  Coronary disease 0.68 0.02 1.97 1.14 to 3.40
  Creatinine level 0.10 0.44 1.10 0.86 to 1.43
  LVEF −0.03 0.01 0.97 0.95 to 0.99
  Tenting area/BSA* 0.67 0.02 1.94 1.09 to 3.47
Impact of BSA- adjusted tenting area >1.35 cm2/m2
  Age −0.02 0.87 0.99 0.97 to 1.03
  Log. EuroScore II 0.02 0.10 1.02 1.00 to 1.05
  Coronary disease 0.69 0.01 2.00 1.16 to 3.41
  Creatinine level 0.08 0.56 1.08 0.83 to 1.40
  LVEF −0.03 0.01 0.97 0.95 to 0.99
  Tenting area/BSA
  >1.35 cm2/m2†
0.84 0.003 2.31 1.32 to 4.04
Impact of annulus- adjusted tenting area
  Age 0.00 0.99 1.00 0.97 to 1.03
  Log. EuroScore II 0.02 0.19 1.02 0.99 to 1.05
  Coronary disease 0.58 0.03 1.79 1.05 to 3.06
  Creatinine level 0.12 0.37 1.12 0.87 to 1.45
  LVEF −0.03 0.004 0.97 0.95 to 0.99
  Tenting area/annulus* 1.04 0.17 2.84 0.64 to 12.6
Impact of annulus- adjusted tenting area >0.76 cm2/cm
  Age −0.01 0.96 1.00 0.97 to 1.03
  Log. EuroScore II 0.02 0.17 1.02 0.99 to 1.05
  Coronary disease 0.58 0.03 1.79 1.05 to 3.06
  Creatinine level 0.09 0.47 1.10 0.85 to 1.42
  LVEF −0.03 0.01 0.97 0.95 to 0.99
  Tenting area/annulus
  >0.76 cm2/cm†
0.55 0.037 1.72 1.03 to 2.89
Impact of gender
  Age −0.01 0.93 0.99 0.97 to 1.03
  Log. EuroScore II 0.02 0.21 1.02 0.99 to 1.04
  Coronary disease 0.50 0.08 1.65 0.95 to 2.87
  Creatinine level 0.12 0.38 1.12 0.87 to 1.45
  LVEF −0.03 0.003 0.97 0.95 to 0.99
  Female sex −0.18 0.51 0.83 0.48 to 1.44
Independent predictors of the composite of survival and freedom from 
adverse cardiac events were assessed by multivariable analysis using 
the Cox proportional hazards regression model.
*Continuous variable.
†Dichotomised variable.
BSA, body surface area; LVEF, left ventricle ejection fraction.
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During the follow- up period, 32/92 (34.8%) patients 
with annulus- indexed MV tenting area >0.76 cm2/cm 
died or had an adverse cardiac event versus 33/148 
(22.3%) patients with annulus- indexed MV tenting area 
≤0.76 cm2/cm. Calculated by Kaplan- Meier analysis, 
annulus- indexed MV tenting area >0.76 cm2/cm was 
significantly associated with the primary study outcome 
(p(log- rank)=0.009) (figure 4B). In addition, multivariable 
analysis revealed that patients with annulus- indexed MV 
tenting area >0.76 cm2/cm had a 1.7 times greater risk for 
experiencing primary study endpoint (HR 1.7; 95% CI 
1.0 to 2.9; p=0.037) (table 3).
Subgrouping by gender
Our study cohort included 105 (44%) female and 135 
(56%) male patients. Comparison of baseline character-
istics between female and male patients revealed signifi-
cantly lower BSA values and lower prevalence of coronary 
artery disease (CAD) in women. Consequently, women 
underwent less concomitant CABG surgery. Furthermore, 
smaller annuloplasty rings were implanted in female 
patients (table 1). The comparison of tenting parameters 
between female and male patients revealed a significantly 
lower MV tenting area, tenting height and annulus diam-
eter in women (table 2). After adjustment to BSA, mean 
values of BSA- indexed tenting area and BSA- indexed 
tenting height were comparable between female and male 
patients. Gender was not significantly associated with the 
primary study endpoint in the Kaplan- Meier analysis (p(log- 
rank)=0.08) (figure 4c) and in the multivariable Cox regres-
sion analysis (HR 0.8;95% CI 0.5 to 1.4;p=0.5).
DISCUSSION
Herewith, we aimed to evaluate the relationship between 
severity of preoperative MV tenting area—indexed to BSA, 
mitral annulus diameter or separated by gender—and 
adverse clinical outcome in patients with FMR who under-
went an isolated MV annuloplasty. Each indexing factor 
correlated significantly with tenting area. BSA- adjusted 
MV tenting area showed the strongest association with 
clinical outcomes in our cohort. BSA- adjusted MV tenting 
area >1.35 cm2/m2 was associated with reduced survival 
and lower freedom of adverse cardiac events following 
isolated MV annuloplasty. Based on these findings, we can 
confirm our initial hypothesis that the severity of indexed 
MV tenting area is associated with clinical outcome in FMR.
Further evidence for the predictive value of tenting 
parameters
Use of indexed MV tenting parameters is limited and 
their predictive value in FMR is still insufficiently 
defined. So far, only two studies addressed BSA- indexed 
or gender- indexed values of MV tenting area.13 17 In the 
former study, published in 2014 by Dwivedi et al, mitral 
Figure 4 (A) Univariate Kaplan- Meier analysis of the composite of survival and freedom of cardiac adverse events using 
tenting area adjusted for body surface area (cut- off point of 1.35 cm2/m2) to divide the study cohort. (B) Univariate Kaplan- 
Meier analysis of the composite of survival and freedom of cardiac adverse events using the tenting area adjusted for annulus 
diameter (cut- off point of 0.76 cm2/cm) to divide the study cohort. (C) Univariate Kaplan- Meier analysis of the composite of 
survival and freedom of cardiac adverse events using gender for subgrouping. BSA, body surface area.
 on F














7von Stumm M, et al. Open Heart 2021;8:e001483. doi:10.1136/openhrt-2020-001483
Valvular heart disease
annular dimensions were analysed in healthy subjects.13 
Average values of BSA- indexed MV tenting area were 1.02 
cm2/m2 in men and 0.93 cm2/m2 in women. The latter 
study, published by Nishino et al, investigated echocardio-
graphic differences between acute and chronic FMR.17 In 
their cohort of patients with chronic FMR, BSA- indexed 
tenting area varied from 1.3 to 1.8 cm2/m2. In our 
cohort, mean values of BSA- adjusted tenting area were 
1.42±0.4 cm2/m2 in male patients and 1.45±0.4 cm2/m2 in 
female patients, which correlate well with the previously 
published data in the context of severe FMR. (table 4).
Indexation of MV tenting area to annulus diameter is 
quite new and we were unable to find any prior data on 
this topic. Of note, MV tenting area correlated strongly 
with the anteroposterior MV annulus diameter in our 
study. However, annulus- indexed MV tenting area (ie, 
continuous variable) showed only a tendency towards 
the primary endpoint prediction in the multivariable 
analysis. We assume that anteroposterior MV annulus 
measurements, as performed in our study, have only a 
limited value to describe the entire MV annular geom-
etry. Given the fact that anteroposterior MV annulus 
measurements did not respect intercommissural annulus 
size and the saddle shape contour of mitral annulus, the 
true MV annular dimensions may be underestimated.18
The impact of gender in MV disease has been widely 
evaluated.12 19 Just recently, a randomised trial by Gius-
tino et al assessed sex- based differences in outcomes after 
MV surgery for severe FMR.12 The authors found signifi-
cantly lower echocardiographic values of left ventricular 
diameters (ie, left ventricular end- diastolic diameter, left 
ventricular end- diastolic volume) and MV apparatus (ie, 
tethering area, mitral annular area) in women. Further-
more, women with FMR experienced significantly higher 
mortality and lower quality of life after MV surgery. Our 
current study revealed smaller echocardiographic dimen-
sions of MV tenting area, anteroposterior MV annulus size 
and MV tenting height in women which is in accordance 
with Giustino’s study. However, there was no difference in 
BSA- adjusted MV tenting parameters between both sexes 
(table 2). Furthermore, we found no sex- related differ-
ences in the clinical outcome after MV repair. However, 
this outcome comparison is blurred by different base-
line characteristics men versus women, as demonstrated 
by better baseline LVEF and lower prevalence of CAD 
requiring simultaneous CABG in women.
In contrast to a novel concept of indexed MV tenting 
area, the impact of absolute (ie, non- indexed) MV 
tenting area in FMR has been extensively analysed in 
previous studies. Our preliminary study showed that non- 
indexed MV tenting area >2.4 cm2 was associated with 
a worse prognosis in patients with FMR following MV 
repair (HR 2.1; p=0.03).5 Other researchers investigated 
also the prognostic value of non- indexed MV tenting area 
in FMR and found that the cut- off value of MV tenting 
area predicting adverse clinical outcomes ranged from 
2.5 to 3.4 cm2 (table 4).6–9 Moreover, recommendations 
of European Association of Echocardiography defined 
non- indexed tenting area >2.5 cm2 as a risk factor for 
recurrent MR following MV repair in FMR.3 However, 
Table 4 Published mean values of tenting area in patients with functional mitral regurgitation (FMR) and non- FMR





Magne et al6 Retrospective 
observational study
2D Echocardiography Non- FMR (n=20) Tenting area (cm2) 0.95±0.2 2.5 cm2
Non- persistent MR 
(n=40)
1.72±0.4
Persistent MR (n=11) 2.70±0.9
Karaca et al7 Prospective 
observational study
2D Echocardiography Non- FMR (n=49) Tenting area (cm2) No values 3.4 cm2
Severe FMR (n=41) No values
Dwivedi et al13 Population- based 
prospective study
2D Echocardiography Healthy subjects 
(n=480)






Nishino et al17 Prospective 
observational study
2D Echocardiography Non- FMR (n=14) Indexed tenting 
area (cm2/m2)
0.42 (0.37–0.44)
Acute FMR (n=44) 1.02 (0.82–1.15)
Chronic FMR (n=36) 1.56 (1.28–1.77)
Nappi et al8 Post hoc analysis 
of prior published 
randomised trial
2D Echocardiography Severe FMR (n=48) Tenting area (cm2) 3.0±0.3 3.1 cm2
Von Stumm et al5 Retrospective 
observational study
2D Echocardiography Severe FMR (n=240) Tenting area (cm2) 2.8±0.8 2.4 cm2
2D, two- dimensional; MR, mitral regurgitation.
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individualised surgical treatment decisions for FMR may 
require adjusted MV tenting severity values to improve 
their prognostic relevance in the prediction of clinical 
outcome. Otherwise, small female or male patients (ie, 
BSA 1.5 m2) with severe FMR and a non- indexed tenting 
area of 2.0 cm2 may be wrongly categorised as atrial FMR 
type and would undergo an isolated annuloplasty despite 
the presence of an extensive LV remodelling.
Putting this all together, there is substantial evidence 
that severity of MV tenting area is associated with outcomes 
in patients with FMR. Adjustment of MV tenting area to 
BSA seems to improve its prognostic value in predicting 
outcomes after MV surgery. However, a prospective study 
is needed to further validate indexed MV tenting param-
eters in FMR treatment.
Individualised FMR treatment based on MV tenting severity
Current surgical FMR treatment includes MV replace-
ment, isolated MV annuloplasty and most recently, MV 
annuloplasty with simultaneous subannular repair.8 
Subannular MV repair techniques address mainly the 
papillary muscles and were developed to actively coun-
teract LV remodelling in addition to annuloplasty, which 
corrects primarily MV annular dilation.20 However, an 
evidence- based treatment algorithm for FMR is still 
missing and it remains unclear, which patients with 
FMR benefit most from simultaneous subannular repair. 
We demonstrated that severe MV tenting, defined as 
MV tenting area >1.35 cm2/m2, is associated with worse 
outcomes following an isolated MV annuloplasty. There-
fore, we believe that patients with MV tenting area 
>1.35 cm2/m2 may benefit most from additional suban-
nular repair.
In summary, an integration of quantitative MV appa-
ratus measurements and of validated individual factors 
(ie, sex, height, weight) is essential to understand the 
key pathogenesis in patients with FMR. Therefore, in 
our opinion, FMR treatment algorithm should involve 
indexed echocardiographic values of MV tenting area 
to allow personalised FMR treatment and subsequent 
improvement of long- term results.
Limitations
Our study possesses all the limitations of a retrospective 
study design. Our study is a single- centre experience, and 
the study population has been retrospectively analyse. 
Furthermore, echocardiographic variables were not vali-
dated by a core laboratory and we used 2D transthoracic 
echocardiography to evaluate MV tenting parameters. 
Therefore, the quantification of tenting volume, inter-
commissural MV annulus diameter and MV annular 
area were not possible without three- dimensional echo 
dataset. Although recurrent mitral regurgitation would 
be an interesting parameter to correlate with the BSA- 
indexed tenting area, no systematic on- site echocardio-
graphic follow- up was available. This is basically due to 
large referral area of our centre, while most patients are 
referred from a radius of >100 km. Therefore, on- site 
echocardiographic follow- up is often impossible due 
to logistic reasons. Echocardiographic follow- up was 
predominantly done by external outpatient cardiologists 
and did not include a standardised protocol to quantify 
recurrent MR. Last, using ROC curves for cut- off point 
analysis neglects time dependency of outcome events. In 
summary, our current findings should be confirmed by a 
consecutive prospective study.
CONCLUSION
Adjustment of MV tenting area to individual anatom-
ical characteristics including body shape (BSA), mitral 
annular dimensions and gender provides new insights 
into FMR mechanisms and may thereby increase its prog-
nostic value. In our study, BSA- adjusted MV tenting area 
>1.35 cm2/m2 was found as a reliable echocardiographic 
marker which predicts reduced survival and lower 
freedom of adverse cardiac events following isolated MV 
annuloplasty. In those patients with FMR with severe MV 
tenting (ie, BSA- indexed MV tenting area >1.35 cm2/m2), 
long- term prognosis could be potentially improved by 
implementing surgical strategies that specifically address 
LV remodelling.
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